Uropathogenic Escherichia coli (UPEC) are common pathogens in urinary tract infections (UTIs), which show resistance to antibiotics. Therefore, there is a need for a vaccine to reduce susceptibility to the infection. In the present study, bioinformatics approaches were employed to predict the best B and T-cell epitopes of UPEC virulence proteins to develop a multiepitope vaccine candidate against UPEC. Then, the efficacy of the candidate was studied with and without Freund adjuvant. Using bioinformatics methods, 3 epitope-rich domains of IutA and FimH antigens were selected to construct the fusion. Molecular docking and Molecular dynamics (MD) simulation were employed to investigate in silico interaction between designed vaccine and Toll-like receptor 4 (TLR4). Our results showed that the levels of IgG and IgA antibodies were improved in the serum and mucosal samples of the vaccinated mice, and the IgG responses were maintained for at least 6 months. The fusion protein was also able to enhance the level of cytokines IFN.γ (Th1), IL.4 (Th2), and IL.17. In challenge experiments, all vaccine combinations showed high potency in the protection of the urinary tract even after 6 months post first injection. The present study indicates that the designed candidate is able to evoke strong protective responses which warrant further studies.
In this study, the silk fibroin nanoparticle (SFNP) was used as a nanoadjuvant in combination with a multiepitopebased vaccine for urinary tract infection (UTI). Nanoparticles containing the fusion protein were analyzed for physicochemical properties, toxicity, release profile, and in vivo potency. The synthesized nanovaccine showed a spherical shape with a mean particle size of 180 nm and an encapsulation efficiency of 88%. Antigen release from SFNPs was 18% after 42 days. The SFNPs showed a zeta potential of −29 mV and had no toxic effect on the L929 cells in vitro. SFNPs in the vaccine formulations promoted humoral and cellular (IFN-γ, IL-4, and IL-17) immune responses in comparison to controls. Immunization of mice with antigen-encapsulated SFNPs significantly increased the total IgG as well as IgG2a/IgG1 ratio. In addition, this formulation triggered concurrently type 1 (Th1) and type 2 (Th2) immune responses, with a Th1-polarized response. Furthermore, highly effective protection of the bladder and kidney against experimental UTI was obtained by using the nanoadjuvant containing the antigen for 6 months. The results demonstrated that SFNPs can be proposed as potent adjuvants or vaccine carriers to develop new and more effective nanovaccine formulations in the future.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.